VRSK vs. CPRX
VRSK (Verisk Analytics, Inc.) and CPRX (Catalyst Pharmaceuticals, Inc.) are both stocks. VRSK operates in Consulting Services (Industrials), while CPRX operates in Biotechnology (Healthcare). Over the past 10 years, VRSK returned 9.35%/yr vs 46.26%/yr for CPRX. At a 0.16 correlation, their price movements are largely independent.
Performance
VRSK vs. CPRX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, VRSK achieves a -17.62% return, which is significantly lower than CPRX's 34.36% return. Over the past 10 years, VRSK has underperformed CPRX with an annualized return of 9.35%, while CPRX has yielded a comparatively higher 46.26% annualized return.
VRSK
- 1D
- 0.99%
- 1M
- 13.83%
- YTD
- -17.62%
- 6M
- -14.96%
- 1Y
- -40.99%
- 3Y*
- -4.78%
- 5Y*
- 1.98%
- 10Y*
- 9.35%
CPRX
- 1D
- -0.03%
- 1M
- 0.64%
- YTD
- 34.36%
- 6M
- 32.77%
- 1Y
- 29.11%
- 3Y*
- 39.03%
- 5Y*
- 40.44%
- 10Y*
- 46.26%
VRSK vs. CPRX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
VRSK Verisk Analytics, Inc. | -17.62% | -18.23% | 16.00% | 36.24% | -22.33% | 10.85% | 39.89% | 37.92% | 13.58% | 18.27% |
CPRX Catalyst Pharmaceuticals, Inc. | 34.36% | 11.84% | 24.15% | -9.62% | 174.74% | 102.69% | -10.93% | 95.31% | -50.90% | 272.38% |
Correlation
The correlation between VRSK and CPRX is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Oct 7, 2009 | 0.16 |
The correlation between VRSK and CPRX shifts across timeframes, from 0.06 (1 year) to 0.20 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
VRSK:
$24.85B
CPRX:
$3.98B
VRSK:
$6.56
CPRX:
$1.74
VRSK:
28.00
CPRX:
18.02
VRSK:
1.53
CPRX:
0.32
VRSK:
8.21
CPRX:
6.68
VRSK:
$3.10B
CPRX:
$596.96M
VRSK:
$2.09B
CPRX:
$378.23M
VRSK:
$1.46B
CPRX:
$313.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
VRSK vs. CPRX — Risk / Return Rank
VRSK
CPRX
VRSK vs. CPRX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Verisk Analytics, Inc. (VRSK) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VRSK | CPRX | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.19 | ||
| Sortino ratioReturn per unit of downside risk | -3.29 | ||
| Omega ratioGain probability vs. loss probability | 0.76 | 1.18 | -0.43 |
| Calmar ratioReturn relative to maximum drawdown | -0.83 | 1.52 | -2.35 |
| Martin ratioReturn relative to average drawdown | -1.35 | 3.46 | -4.80 |
Loading charts...
Drawdowns
VRSK vs. CPRX - Drawdown Comparison
The maximum VRSK drawdown since its inception was -50.81%, smaller than the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for VRSK and CPRX.
Loading charts...
Drawdown Indicators
| VRSK | CPRX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -50.81% | -94.25% | +43.44% |
Max Drawdown (1Y)Largest decline over 1 year | -49.57% | -19.18% | -30.39% |
Max Drawdown (3Y)Largest decline over 3 years | -50.81% | -27.29% | -23.52% |
Max Drawdown (5Y)Largest decline over 5 years | -50.81% | -45.37% | -5.44% |
Max Drawdown (10Y)Largest decline over 10 years | -50.81% | -64.87% | +14.06% |
Current DrawdownCurrent decline from peak | -42.35% | -0.03% | -42.32% |
Average DrawdownAverage peak-to-trough decline | -7.24% | -51.96% | +44.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 30.61% | 9.84% | +20.77% |
Volatility
VRSK vs. CPRX - Volatility Comparison
Verisk Analytics, Inc. (VRSK) has a higher volatility of 9.55% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 0.47%. This indicates that VRSK's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| VRSK | CPRX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.55% | 0.47% | +9.08% |
Volatility (6M)Calculated over the trailing 6-month period | 25.41% | 23.17% | +2.24% |
Volatility (1Y)Calculated over the trailing 1-year period | 31.55% | 33.28% | -1.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.30% | 47.77% | -23.47% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.01% | 60.39% | -36.38% |
Dividends
VRSK vs. CPRX - Dividend Comparison
VRSK's dividend yield for the trailing twelve months is around 1.01%, while CPRX has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
CPRX Catalyst Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
VRSK Verisk Analytics, Inc. | 1.01% | 0.80% | 0.57% | 0.57% | 0.70% | 0.51% | 0.52% | 0.67% |
Financials
VRSK vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Verisk Analytics, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
VRSK vs. CPRX - Profitability Comparison
VRSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Verisk Analytics, Inc. reported a gross profit of 546.00M and revenue of 782.60M. Therefore, the gross margin over that period was 69.8%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a gross profit of 0.00 and revenue of 149.39M. Therefore, the gross margin over that period was 0.0%.
VRSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Verisk Analytics, Inc. reported an operating income of 352.20M and revenue of 782.60M, resulting in an operating margin of 45.0%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported an operating income of 73.23M and revenue of 149.39M, resulting in an operating margin of 49.0%.
VRSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Verisk Analytics, Inc. reported a net income of 234.20M and revenue of 782.60M, resulting in a net margin of 29.9%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Catalyst Pharmaceuticals, Inc. reported a net income of 63.73M and revenue of 149.39M, resulting in a net margin of 42.7%.
Frequently Asked Questions
VRSK and CPRX have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
VRSK has higher volatility (9.55%) compared to CPRX (0.47%). In terms of maximum drawdown, VRSK dropped -50.81% vs CPRX's -94.25%.
CPRX currently has the higher Sharpe Ratio (0.89 vs -1.30), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for VRSK and CPRX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer